Inhibition of lymphocyte function by head and neck carcinoma cell line soluble factors

Archives of Otolaryngology - Head and Neck Surgery

Volumn 123, Issue 8, 1997, Pages 855-862

  Bailet, Jeffrey W ^a,b   Lichtenstein, Alan ^a,b,c   Chen, Ge ^a   Mickel, Robert A ^a,b,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Vet Aff Med Ctr W Los A ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; TREATMENT OUTCOME;

EID: 0030852924     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.1997.01900080089011     Document Type: Article

References (31)

1. Herberman RB. Natural cell mediated immunity. Adv Clin Res. 1978;27:305-377.
2. Rosenberg SA. The adoptive immunotherapy of cancer using the transfer of activated lymphoid cells and interleukin-2. Semin Oncol. 1988;13:200-206.
3. Lafreniere R, Rosenberg SA. Adoptive immunotnerapy of hepatic metastases with lymphokine activated (LAK) cells and recombinant interleukin-2 (RIL-2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and adenocarcinoma. J Immunol. 1985;135:4273-4280.
4. Mule JJ, Shu S, Schwarz SL, Rosenberg SA. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin 2. Science. 1984;225:1487-1489.
5. Rosenberg SA, Lotze MT, Mule JJ. New approaches to immunotherapy of cancer using interleukin-2. Ann Intern Med. 1988;108:853-854.
6. Topalian SL, Solomon D, Avis FP, et al. Immunotherapy of patients with advanced cancer using tumor-inliltrating lymphocytes and recombinant interleu-kin-2: a pilot study. J Clin Oncol. 1988:6:839-853.
7. Bredenkamp JK, Leess FR, Lichtenstein A, Mickel RA. Regional and systemic autologous lymphokine-activated cytotoxicity of head and neck patients. Surg Forum. 1989;40:530-533.
8. Wang MB, Lichtenstein A, Mickel RA. Hierarchical immunosuppression of regional lymph nodes in patients with head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg. 1991;105:517-527.
9. Strasnick B, Lagos N, Lichtenstein A, Mickel RA. Suppression of lymphokine-activated killer cell cytotoxicity by a soluble factor produced by squamous tumors of the head and neck. Otolaryngol Head Neck Surg. 1990;103:537-549.
10. Boyum A. Isolation of mononuclear cells and of granulocytes from human blood: isolation of mononuclear cells by one centrifugation and of granulocytes by combining centrifugation and sedimentation at 1 G. Scand J Clin Lab Invest. 1968; 21(suppl 97):77-89.
11. 51chromium-release assay as used for the quantitave measurement of cell-mediated lysis in vitro. In: Bloom BR, David JK, eds. In Vitro Methods of Cell-Mediated Immunity. Orlando, Fla: Academic Press Inc; 1976:423-428.
12. 51Cr release assay for long-term follow-up of NK activity of individual mice. J Immunol Methods. 1986;93: 193-200.
13. Penhale WJ, Farmer A, MacCuish AC, Irvine WJ. A rapid micro-method for the phytohaemaggluttin-induced human lymphocyte transformation test. Clin Exp Immunol. 1974;18:155-167.
14. Newbill ET, Johns ME. Immunology of dead and neck cancers. Crit Rev Clin Lab Sci. 1983;19:1-25
15. Lichtenstein A, Zighelboim J, Dorey F, Brossman S, Fahey JL. Comparison of immune derangements in patients with different malignancies. Cancer. 1980; 45:2090-2095.
16. Vinzenz K, Misksche M. Natural cytotoxicity in draining lymph nodes of squamous cell cancer in the maxillofacial region. J Oral Maxillofac Surg. 1987;45: 42-47.
17. Kessler DJ, Mickel RA, Lichtenstein A. Deppresed natural killer cell cytotoxicty in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Arch Otolaryngol Head Neck Surg. 1988;114:313-318.
18. Racz T, Sacks PG, Taylor DL, Shantz SP. Natural killer cell lysis of head and neck cancer. Arch Otolaryngol Head Heck Surg. 1989;115:1322-1328.
19. Herberman RB. Cancer therapy by biological response modifiers. Clin Physiol Biochem. 1987;5:238-248.
20. Alessi DM, Hutcherson RW, Mickel RA. Production of lymphokine-activated lymphocytes. Arch Otolaryngol Head Neck Surg. 1989;115:725-730.
21. Uchida A, Misksche M. Suppressor cells for natural killer activity in carcinomatous pleural effusions of cancer patients. Cancer Immunol Immunother. 1981; 11:255-263.
22. Kiczka W, Szkaradkiewicz A. Suppression of monocyte mediated anti U562 cytotoxicity by soluble factors in the serum of cancer patients and in the super-nantant of K562 cell culture, Immunol Lett. 1986;13:127-131.
23. Hirte H, Clark DA. Generation of lymptiokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-β as a suppressive factor. Cancer Immunol Immunother. 1991;32:296-302.
24. Lapointe H, Lampe H, Banerjee D. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses Otolaryngol Head Neck Surg. 1992;106:149-156.
25. Defries RV, Golub SH. Characteristics and mechanism of IFN-gamma-induced protection of human tumor cells from lysis by lymphokine-activated killer cells. J Immunol. 1988;140:3686-3693.
26. Balch CM, Dougherty PA, Tilden AB. Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg. 1982;196: 645-650.
27. McCormick KJ, Panje WR. Indomethacin-induced augmentation of lymphoproliferative responses in patients with head and neck cancer. Cancer Immunol Immunother. 1986;21:226-232.
28. Wanebo HJ, Rilet T, Katz D, Pace RC, et al. Indomethacin sensitive suppressor-cell activity in head and neck cancer patients: the role of the adherent mono-nuclear cell. Cancer. 1988;61:462-474.
29. Mohagheghpour NB, Parhami K, Dowlatshaki D, et al. Immunoregulatory properties of human esophageal tumor extract. J Immunol. 1979;122:1350-1358.
30. Ebert NC, Roberts AI, O'Connell SM, Robertson FM, Nagase H. Characterization of an immunosuppressive factor derived from colon cancer. J Immunol. 1987; 138:2161-2168.
31. 1. J Immunol. 1988;140:2312-2316.